Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia

Drugs and Aging

Volumn 22, Issue 7, 2005, Pages 615-626

  Meinhold, Jane M ^a   Blake, Lesley M ^b   Mini, Louis J ^c   Welge, Jeffrey A ^d   Schwiers, Michael ^d   Hughes, Anthony ^e  

^a ABBOTT LABORATORIES   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c The University of Chicago   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Beverly Enterprises   (United States)

Author keywords

Antipsychotics; Behavioural disorders; Cognition disorders; Dementia; Elderly; Valproate semisodium

Indexed keywords

VALPROATE SEMISODIUM;

ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DATA BASE; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; LINEAR REGRESSION ANALYSIS; NURSING HOME; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 24044477555     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522070-00007     Document Type: Article

References (36)

1. 1. D Bachman P Weif P Linn 1992 Prevalence of dementia and probably senile dementia of the Alzheimer type in the Framingham study Neurology 42 115 9 1734291 10.1212/WNL.42.1.115 1:STN:280:DyaK387jtFaluw%3D%3D Bachman D, Weif P, Linn P. Prevalence of dementia and probably senile dementia of the Alzheimer type in the Framingham study. Neurology 1992; 42: 115–9
2. 2. CG Lyketsos M Steinberg JT Tschanz 2000 Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging Am J Psychiatry 157 708 14 10784462 10.1176/appi.ajp.157.5.708 1:STN:280:DC%2BD3c3ks12hsg%3D%3D Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708–14
3. 3. P Tariot 1996 Treatment strategies for agitation and psychosis in dementia J Clin Psychiatry 57 21 9 9024333 1:CAS:528:DyaK2sXhtFGjt7Y%3D Tariot P. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996; 57: 21–9
4. 4. Dybicz S, Erwin WG, Helbers L, et al. Frequency and treatment patterns of behavioral symptoms in skilled nursing facility residents [abstract]. American Society of Consultant Pharmacists 33rd Annual Meeting, poster presentation 2002; 2002 Nov 13–16; Anaheim (CA)
5. 5. PN Tariot MS Ismail 2002 Use of quetiapine in elderly patients J Clin Psychiatry 63 Suppl.13 21 6 12562143 1:CAS:528:DC%2BD3sXjtV2gsg%3D%3D Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 63Suppl. 13: 21–6
6. 6. IR Katz DV Jeste JE Mintzer 1999 Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial J Clin Psychiatry 60 107 15 10084637 10.4088/JCP.v60n0207 1:CAS:528:DyaK1MXhvVSiur0%3D Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–15
7. 7. H Brodaty D Ames J Snowdon 2003 A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia J Clin Psychiatry 54 134 43 10.4088/JCP.v64n0205 Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 54: 134–43
8. 8. PP Deyn De K Rabheru A Rasmussen 1999 A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia Neurology 53 946 55 10496251 10.1212/WNL.53.5.946 De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55
9. 9. JS Street WS Clark KS Gannon 2000 Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer’s dementia Arch Gen Psychiatry 57 968 76 11015815 10.1001/archpsyc.57.10.968 1:CAS:528:DC%2BD3cXnsFenur0%3D Street JS, Clark WS, Gannon KS, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer’s dementia. Arch Gen Psychiatry 2000; 57: 968–76
10. 10. FDA. FDA Public Health Advisory [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/antipsychotics [Accessed 2005 Apr 4]
11. 11. IB Frenchman C Capo H Kass 2000 Effect of treatment with divalproex sodium and lorazepam in residents of long-term-care facilities with dementia-related anxiety or agitation: retrospective chart review Curr Ther Res 61 621 9 10.1016/S0011-393X(00)88014-5 1:CAS:528:DC%2BD3cXnt1Kms74%3D Frenchman IB, Capo C, Kass H. Effect of treatment with divalproex sodium and lorazepam in residents of long-term-care facilities with dementia-related anxiety or agitation: retrospective chart review. Curr Ther Res 2000; 61: 621–9
12. 12. PN Tariot 1999 Treatment of agitation in dementia J Clin Psychiatry 60 11 20 10335667 10.4088/JCP.v60n1007 Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999; 60: 11–20
13. 13. PN Tariot R Erb CA Podgorski 1998 Efficacy and tolerability of carbamazepine for agitation and aggression in dementia Am J Psychiatry 155 54 61 9433339 1:STN:280:DyaK1c%2FpsV2isQ%3D%3D Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54–61
14. 14. PN Tariot LS Schneider JE Mintzer 2001 Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial Curr Ther Res Clin Exp 62 51 67 10.1016/S0011-393X(01)80042-4 1:CAS:528:DC%2BD3MXhtlKhurw%3D Tariot PN, Schneider LS, Mintzer JE. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001; 62: 51–67
15. 15. AP Porsteinsson PN Tariot R Erb 1997 An open trial of valproate for agitation in geriatric neuropsychiatric disorders Am J Geriatr Psychiatry 5 344 51 9363292 10.1097/00019442-199700540-00010 1:STN:280:DyaK1c%2FivFOiuw%3D%3D Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997; 5: 344–51
16. 16. AP Porsteinsson PN Tariot LJ Jakimovich 2003 Valproate therapy for agitation in dementia: open-label extension of a double-blind trial Am J Geriatr Psychiatry 11 434 40 12837672 Porsteinsson AP, Tariot PN, Jakimovich LJ, et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003; 11: 434–40
17. 17. AP Porsteinsson PN Tariot R Erb 2001 Placebo-controlled study of divalproex sodium for agitation in dementia Am J Geriatr Psychiatry 9 58 66 11156753 1:STN:280:DC%2BD3M3htFGqtw%3D%3D Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58–66
18. 18. F Grossman 1998 A review of anticonvulsants in treating agitated demented elderly patients Pharmacotherapy 18 600 6 9620110 1:CAS:528:DyaK1cXkt1KjtLg%3D Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy 1998; 18: 600–6
19. 19. GS Alexopoulos JM Silver DA Kahn 1998 The expert consensus guideline series: treatment of agitation in older persons with dementia Postgrad Med 103 s-4 1 88 Alexopoulos GS, Silver JM, Kahn DA, et al. The expert consensus guideline series: treatment of agitation in older persons with dementia. Postgrad Med 1998; 103(s-4): 1–88
20. 20. AM Mellow C Solano-Lopez S Davis 1993 Sodium valproate in the treatment of behavioral disturbance in dementia J Geriatr Psychiatry Neurol 6 205 9 8251047 1:STN:280:DyaK2c%2Fnt1SlsQ%3D%3D Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993; 6: 205–9
21. 21. RJ Goldberg 1999 The use of adjunctive divalproex for neuroleptic unresponsive behavioral disturbances in nursing home residents with dementia Ann Long Term Care 7 63 6 Goldberg RJ. The use of adjunctive divalproex for neuroleptic unresponsive behavioral disturbances in nursing home residents with dementia. Ann Long Term Care 1999; 7: 63–6
22. 22. PN Tariot R Loy JM Ryan 2002 Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales Adv Drug Deliv Rev 54 1567 77 12453674 10.1016/S0169-409X(02)00153-9 1:CAS:528:DC%2BD38XovFemt7c%3D Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002; 54: 1567–77
23. 23. HK Manji GJ Moore G Chen 2000 Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic depressive illness Biol Psychiatry 48 740 54 11063971 10.1016/S0006-3223(00)00979-3 1:CAS:528:DC%2BD3cXns12gurg%3D Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic depressive illness. Biol Psychiatry 2000; 48: 740–54
24. 24. G Chen WZ Zeng PX Yuan 1999 The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CANS J Neurochem 72 879 82 9930766 10.1046/j.1471-4159.1999.720879.x 1:CAS:528:DyaK1MXmt1yktw%3D%3D Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CANS. J Neurochem 1999; 72: 879–82
25. 25. R Loy PN Tariot 2002 Neuroprotective properties of valproate: potential benefit for AD and tauopathies J Mol Neurosci 19 303 7 12540056 10.1385/JMN:19:3:301 1:CAS:528:DC%2BD3sXislGgtA%3D%3D Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J Mol Neurosci 2002; 19: 303–7
26. 26. K Frederiksen P Tariot E DeJonghe 1996 Minimum Data Set Plus (MDS +) scores compared with scores from five rating scales J Am Geriatr Soc 44 305 9 8600202 1:STN:280:DyaK287osVKqsg%3D%3D Frederiksen K, Tariot P, DeJonghe E. Minimum Data Set Plus (MDS +) scores compared with scores from five rating scales. J Am Geriatr Soc 1996; 44: 305–9
27. 27. JN Morris RN Jones BE Fries 2004 Convergent validity of minimum data set-based performance quality indicators in postacute care settings Am J Med Qual 19 242 7 15620075 10.1177/106286060401900603 Morris JN, Jones RN, Fries BE, et al. Convergent validity of minimum data set-based performance quality indicators in postacute care settings. Am J Med Qual 2004; 19: 242–7
28. 28. W Sandborn F Bendfeldt R Hamdy 1995 Valproic acid for physically aggressive behavioral in geriatric patients Am J Geriatr Psychiatry 3 239 42 10.1097/00019442-199522330-00007 Sandborn W, Bendfeldt F, Hamdy R. Valproic acid for physically aggressive behavioral in geriatric patients. Am J Geriatr Psychiatry 1995; 3: 239–42
29. 29. S Gupta R O’Connell A Parekh 1998 Efficacy of valproate for agitation and aggression in dementia: case reports Int J Geriatr Psychopharm 1 244 8 Gupta S, O’Connell R, Parekh A, et al. Efficacy of valproate for agitation and aggression in dementia: case reports. Int J Geriatr Psychopharm 1998; 1: 244–8
30. 30. RC Sival PM Haffmans PP Gent van 1994 The effects of sodium valproate on disturbed behavioral in dementia J Am Geriatr Soc 42 8 906 7 8046208 1:STN:280:DyaK2czitFOgtQ%3D%3D Sival RC, Haffmans PM, van Gent PP, et al. The effects of sodium valproate on disturbed behavioral in dementia. J Am Geriatr Soc 1994; 42(8): 906–7
31. 31. M Narayan JC Nelson 1997 Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic J Clin Psychiatry 58 351 4 9515973 10.4088/JCP.v58n0804 1:CAS:528:DyaK2sXlvFartrw%3D Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997; 58: 351–4
32. 32. ME Kunik L Puryear CA Orengo 1998 The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances Int J Geriatr Psychiatry 13 29 34 9489578 10.1002/(SICI)1099-1166(199801)13:1<29::AID-GPS726>3.0.CO;2-Z 1:STN:280:DyaK1c7kvFahsA%3D%3D Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998; 13: 29–34
33. 33. A Lott SL McElroy MA Keys 1995 Valproate in the treatment of behavioral agitation in elderly patients with dementia J Neuropsychiatry Clin Neurosci 7 314 9 7580190 1:STN:280:DyaK28%2Fns1SjsA%3D%3D Lott A, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci 1995; 7: 314–9
34. 34. S Haas K Vincent J Holt 1997 Divalproex: a possible treatment alternative for demented, elderly aggressive patients Ann Clin Psychiatry 9 3 145 7 9339879 1:STN:280:DyaK2svnvFOqug%3D%3D Haas S, Vincent K, Holt J, et al. Divalproex: a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry 1997; 9(3): 145–7
35. 35. JW Kasckow SL McElroy RL Cameron 1997 A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the Behave-AD and CGI rating scales Curr Ther Res 58 981 9 10.1016/S0011-393X(97)80065-3 1:CAS:528:DyaK1cXltVGhtw%3D%3D Kasckow JW, McElroy SL, Cameron RL, et al. A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the Behave-AD and CGI rating scales. Curr Ther Res 1997; 58: 981–9
36. 36. N Herrmann 1998 Valproic acid treatment of agitation in dementia Can J Psychiatry 43 69 72 9494750 1:STN:280:DyaK1c7lsFymtg%3D%3D Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43: 69–72